JP6998092B1 - SARS-CoV-2とACE2タンパク質との結合阻害用組成物 - Google Patents
SARS-CoV-2とACE2タンパク質との結合阻害用組成物 Download PDFInfo
- Publication number
- JP6998092B1 JP6998092B1 JP2021033248A JP2021033248A JP6998092B1 JP 6998092 B1 JP6998092 B1 JP 6998092B1 JP 2021033248 A JP2021033248 A JP 2021033248A JP 2021033248 A JP2021033248 A JP 2021033248A JP 6998092 B1 JP6998092 B1 JP 6998092B1
- Authority
- JP
- Japan
- Prior art keywords
- chlorine dioxide
- ppm
- sars
- cov
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
亜塩素酸ナトリウム水溶液に塩酸を加えて発生する二酸化塩素ガスを蒸留水に導入し、55mMの二酸化塩素水溶液として調整した。これを使用直前まで遮光し、4℃にて気密容器に保存した。
実験結果を以下の表に示す。
Claims (4)
- SARS-CoV-2のスパイク(S)タンパク質とアンジオテンシン変換酵素2(ACE2)タンパク質との結合を阻害する方法であって、
SARS-CoV-2が存在する場所に、二酸化塩素ガス濃度が0.00001ppm~230ppmとなるように有効量の二酸化塩素を含むガス状組成物を適用するステップを含む、
方法(ただし、ヒトの生体への適用を除く)。 - 請求項1に記載の方法であって、
前記SARS-CoV-2が存在する場所に有効量の二酸化塩素を含むガス状組成物を適用するステップが、前記場所における二酸化塩素ガス濃度が0.00001ppm~0.3ppmとなるように前記二酸化塩素を含むガス状組成物を適用するステップである、
方法。 - 請求項1に記載の方法であって、
前記SARS-CoV-2が存在する場所に有効量の二酸化塩素を含むガス状組成物を適用するステップが、前記場所における二酸化塩素ガス濃度が0.3ppm~230ppmとなるように前記二酸化塩素を含むガス状組成物を適用するステップである、
方法。 - 請求項3に記載の方法であって、
前記SARS-CoV-2が存在する場所に有効量の二酸化塩素を含むガス状組成物を適用するステップが、前記場所における二酸化塩素ガス濃度が10ppm~230ppmとなるように前記二酸化塩素を含むガス状組成物を適用するステップである、
方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021033248A JP6998092B1 (ja) | 2020-06-24 | 2021-03-03 | SARS-CoV-2とACE2タンパク質との結合阻害用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020108856A JP6854029B1 (ja) | 2020-06-24 | 2020-06-24 | SARS−CoV−2とACE2タンパク質との結合阻害用組成物 |
JP2021033248A JP6998092B1 (ja) | 2020-06-24 | 2021-03-03 | SARS-CoV-2とACE2タンパク質との結合阻害用組成物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020108856A Division JP6854029B1 (ja) | 2020-06-24 | 2020-06-24 | SARS−CoV−2とACE2タンパク質との結合阻害用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6998092B1 true JP6998092B1 (ja) | 2022-01-24 |
JP2022024981A JP2022024981A (ja) | 2022-02-09 |
Family
ID=87853040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021033248A Active JP6998092B1 (ja) | 2020-06-24 | 2021-03-03 | SARS-CoV-2とACE2タンパク質との結合阻害用組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6998092B1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007061092A1 (ja) | 2005-11-28 | 2007-05-31 | Taiko Pharmaceutical Co., Ltd. | 浮遊ウイルス感染対策方法 |
-
2021
- 2021-03-03 JP JP2021033248A patent/JP6998092B1/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007061092A1 (ja) | 2005-11-28 | 2007-05-31 | Taiko Pharmaceutical Co., Ltd. | 浮遊ウイルス感染対策方法 |
Non-Patent Citations (5)
Title |
---|
HOFFMANN, M. et. al.,SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inh,Cell,2020年04月16日,181,271-280 |
WALLS, A. C. et. al.,Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein,Cell,2020年04月16日,180,281-292 |
二酸化塩素の自主運営基準設定のための評価について-ガス製品-,日本二酸化塩素工業会,2014年,https://monoist.atmarkit.co.jp/mn.articles/2005/28/news010.html |
新型コロナウイルスに対し98%以上の消毒効果を確認,MONOist[online],2020年05月28日,https://monoist.atmarkit.co.jp/mn.articles/2005/28/news010.html,[検索日2020.10.13] |
消毒剤使用指南,National Health Commission of the People's Republic of China[online],2020年02月18日,www.nhc.gov.cn/xcs/zhengcwj/202002/b9891e8c86d141a08ec45c6a18e21dc2.shtml,[検索日2021.05.06] |
Also Published As
Publication number | Publication date |
---|---|
JP2022024981A (ja) | 2022-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101426570B1 (ko) | 부유 바이러스 감염 대책 방법 | |
Mülsch et al. | LY 83583 (6-anilino-5, 8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation | |
RU2008109244A (ru) | Способ санитарного убоя животных и мешок, используемый при таком способе | |
KR100772054B1 (ko) | 조류 인플루엔자 소독용 조성물 | |
Dodds et al. | Effects on fracture healing of an antagonist of the vitamin K cycle | |
JP6998092B1 (ja) | SARS-CoV-2とACE2タンパク質との結合阻害用組成物 | |
JP6854029B1 (ja) | SARS−CoV−2とACE2タンパク質との結合阻害用組成物 | |
Insignares-Carrione et al. | Chlorine dioxide in COVID-19: hypothesis about the possible mechanism of molecular action in SARS-CoV-2 | |
CN109197894A (zh) | 环保速溶复方单过硫酸氢钾消毒剂及其制备方法 | |
CN112120042A (zh) | 一种高效灭菌的次氯酸消毒液及其制备方法 | |
JP2003222621A (ja) | 過酸化水素を含有する気体環境中の微生物の存在の試験方法 | |
Gidari et al. | SARS-CoV-2 survival on surfaces and the effect of UV-C light. Viruses 2021; 13: 408 | |
McClaskey et al. | Clinical trials for pathogen reduction in transfusion medicine: a review | |
Wunderlich et al. | Nitric oxide synthases are crucially involved in the development of the severe cardiomyopathy of caveolin-1 knockout mice | |
TWI795348B (zh) | 醫療廢棄物容器之廢棄前處理方法 | |
Bastin et al. | Aerobic Conditions and Endogenous Reactive Oxygen Species Reduce the Production of Infectious MS2 phage by Escherichia coli. Viruses 2021, 13, 1376 | |
RU2218185C2 (ru) | Средство "делансаль" для дезинфекции и стерилизации материалов, инструментов и оборудования медицинского назначения и способ его приготовления | |
JP2007039395A (ja) | ヘルペスウイルス不活化剤 | |
Hamilton et al. | Surface Inactivation of a SARS-CoV-2 Surrogate with Hypochlorous Acid is Impacted by Surface Type, Contact Time, Inoculum Matrix, and Concentration | |
AU749601B2 (en) | A process for sterilizing a biologically contaminated enclosure | |
JP2022182924A (ja) | 亜塩素酸水を調製するための組成物 | |
Andrews | The sensitivity of axenic 200: NIH Entamoeba histolytica to bacitracin and its zinc salt | |
GEORGE M STERNBERGJ ournal of American Medical Association | THE DISINFECTION OF EXCRETA | |
Kopprasch et al. | Characterization of the chemiluminescence response of polymorphonuclear leukocytes stimulated with urate crystals | |
Due | John Day: a colonial medical life |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210311 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210423 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210827 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6998092 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |